IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

FOURNIER, ET AL. EXAMINER:

UNASSIGNED

SERIAL NO.

UNASSIGNED

ART UNIT :

UNASSIGNED

FILED

JANUARY 29, 2004

FOR

POLYPEPTIDES CAPABLE OF INTERACTING WITH

HUMAN TOPOISOMERASE III ALPHA

CERTIFICATE OF MAILING UNDER 37 CFR § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as EXPRESS MAIL with EXPRESS MAIL LABEL NO. EL964838896US in an envelope addressed MAIL STOP PATENT APPLICATIONS COMMISSIONER FOR PATENTS, BOX 1450, ALEXANDRIA, VA 33212-1450 on January 29, 2004.

Delia Coychlin

Welia Congles 1/29/04 (Signature and Date)

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Mail Stop Patent Application Commissioner for Patents Box 1450 Alexandria, VA 22313-1450 Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed paper copy of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the paper copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Sequence Listing can be found in the application as filed.

Fees

No additional fees are believed to be necessitated by the foregoing Response.

However, should this be erroneous, authorization is hereby given to charge Deposit

Account No. 18-1982 for any underpayment, or credit any overages.

Respectfully submitted,

William C. Coppola

Registration No. 41,686

AVENTIS PHARMACEUTICALS INC. Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-4854